2024 Results
Revenue for the year
£126.0m
+2%
Adjusted EBITA
£25.6m
+6%
Adjusted profit before tax
£27.6m
+13%
Organic revenue growth
9%
2023: 13%
Adjusted PBT margin
20%
2023: 20%
Profit before tax
£48.5m
2023: £24m
Adjusted earnings per share
22.96p
+7%
Total dividend
11.3p
+13%
Group net cash excl. lease liabilities
£67.8m
+61%
Basic earnings/(loss) per share
45.92p
2023: 22.94p
Final dividend
8.3p
2023: 7.3p
Cash conversion at
116%
2023: 138%
Chief Executive's Statement
We have delivered another strong year, in line with our strategy with notably strong increases in revenues, profits and cash generation. Margins have also continued to improve strongly. We continued to focus on consolidating our already strong presence in the large, growing and rapidly evolving international GRC markets and significantly enhanced our capabilities with the acquisition of Astutis in the Health, Safety and Environment (‘HSE’) sector. We sold our European Healthcare businesses and MiExact. We now have a higher quality portfolio of growing international businesses and continue to pursue various opportunities to invest in acquisitions to improve our growth and profitability. We have also started to transfer our businesses onto our single operating platform, which will continue to improve our performance. We have had a good start to the current financial year, with revenues and profits in line with expectations.
Chief Executive Officer